Contineum Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Contineum Therapeutics, Inc. | CTNM - NASDAQ |
$16.00-$18.00 | $16.00 | $14.50 | 6.875 million | 4/5/2024 |
| Goldman Sachs, Morgan Stanley, Stifel, RBC Capital | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2024-03-15 Terms Added 2024-04-01 | ||||||
Contineum Therapeutics, Inc. Quote & Chart - Click for current quote - CTNM
IPO Boutique aggregates information on public companies and private companies, such as "CTNM" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Contineum Therapeutics, Inc. (adapted from Contineum Therapeutics, Inc. prospectus):
They are a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications with high unmet need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications with high unmet need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "CTNM" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.